CASI

CASI Pharmaceuticals, Inc.

7.27 USD

Last updated Dec 8, 16:49 UTC

Yesterday HIGH

$7.64

Yesterday LOW

$6.56

52w HIGH

$7.64

52w LOW

$1.45

EPS

-0.35

PE

-20.77

Next Earnings

Apr 24, 2024

Overview News Government Trades

CASI Pharmaceuticals, Inc. stock is up 77.32% since 30 days ago. The next earnings date is Apr 24, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 December’s closed higher than November. 100% of analysts rate it a buy.

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL)

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Rockville, United States Of America

Website

casipharmaceuticals.com

Benzinga Newsdesk

Thu Dec 15, 2022

CASI Pharmaceuticals' Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical
Benzinga Newsdesk

Wed Nov 16, 2022

BTIG Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Justin Zelin maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $21 to $10.
Benzinga Newsdesk

Tue Nov 15, 2022

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $12 to $10.
Benzinga Newsdesk

Mon Nov 14, 2022

CASI Pharmaceuticals Q3 EPS $(0.38) Up From $(0.73) YoY, Sales $10.21M Up From $8.11M YoY

CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.38) per share. This is a 47.95 percent increase over losses of $(0.73) per share from the same period last year. The company reported $10.21 million in
Lisa Levin

Mon Sep 26, 2022

Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Benzinga Insights

Fri Sep 23, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers
Benzinga Newsdesk

Fri Sep 23, 2022

CASI Pharmaceuticals Announces Exit Of Juventas Investment To Strengthen Balance Sheet

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products ("CASI"), today announced that CASI
Lisa Levin

Fri Sep 9, 2022

$2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga Insights

Fri Sep 9, 2022

CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q2, CASI Pharmaceuticals's (NASDAQ:CASI) reported sales totaled $8.57 million. Despite a 10.8% increase in earnings, the company posted a loss of $7.49 million.
Charles Gross

Wed Sep 7, 2022

CASI Pharmaceuticals and BioInvent Announced Dosing of First patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory non-Hodgkin's lymphoma in China

CASI Pharmaceuticals, Inc.